|
1
|
Akbari-Birgani S, Paranjothy T, Zuse A,
Janikowski T, Cieślar-Pobuda A, Likus W, Urasińska E, Schweizer F,
Ghavami S, Klonisch T and Łos MJ: Cancer stem cells,
cancer-initiating cells and methods for their detection. Drug
Discov Today. 21:836–842. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gerweck LE and Wakimoto H: At the
crossroads of cancer stem cells, radiation biology, and radiation
oncology. Cancer Res. 76:994–998. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dalerba P, Cho RW and Clarke MF: Cancer
stem cells: Models and concepts. Annu Rev Med. 58:267–284. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wicha MS: Cancer stem cells and
metastasis: Lethal seeds. Clin Cancer Res. 12:5606–5607. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Norton L: Cancer stem cells, EMT, and
seeding: A rose is a rose is a rose? Oncology (Williston Park).
25:3032. 2011.PubMed/NCBI
|
|
6
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ginestier C, Hur MH, Charafe-Jauffret E,
Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG,
Liu S, et al: ALDH1 is a marker of normal and malignant human
mammary stem cells and a predictor of poor clinical outcome. Cell
stem cell. 1:555–567. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lo PK, Kanojia D, Liu X, Singh UP, Berger
FG, Wang Q and Chen H: CD49f and CD61 identify Her2/neu-induced
mammary tumor-initiating cells that are potentially derived from
luminal progenitors and maintained by the integrin-TGFβ signaling.
Oncogene. 31:2614–2626. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Burgess R and Huang RP: Cancer stem cell
biomarker discovery using antibody array technology. Adv Clin Chem.
73:109–125. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pfeffer SR: Rab GTPases: Specifying and
deciphering organelle identity and function. Trends Cell Biol.
11:487–491. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Seabra MC, Mules EH and Hume AN: Rab
GTPases, intracellular traffic and disease. Trends Mol Med.
8:23–30. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pereira-Leal JB and Seabra MC: Evolution
of the Rab family of small GTP-binding proteins. J Mol Biol.
313:889–901. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tolmachova T, Ramalho JS, Anant JS,
Schultz RA, Huxley CM and Seabra MC: Cloning, mapping and
characterization of the human RAB27A gene. Gene. 239:109–116. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ménasché G, Pastural E, Feldmann J,
Certain S, Ersoy F, Dupuis S, Wulffraat N, Bianchi D, Fischer A, Le
Deist F and de Saint Basile G: Mutations in RAB27A cause Griscelli
syndrome associated with haemophagocytic syndrome. Nature Genet.
25:173–176. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Griscelli C, Durandy A, Guy-Grand D,
Daguillard F, Herzog C and Prunieras M: A syndrome associating
partial albinism and immunodeficiency. Am J Med. 65:691–702. 1978.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fukuda M, Kanno E, Saegusa C, Ogata Y and
Kuroda TS: Slp4-a/granuphilin-a regulates dense-core vesicle
exocytosis in PC12 cells. J Biol Chem. 277:39673–39678. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yi Z, Yokota H, Torii S, Aoki T, Hosaka M,
Zhao S, Takata K, Takeuchi T and Izumi T: The Rab27a/granuphilin
complex regulates the exocytosis of insulin-containing dense-core
granules. Mol Cell Biol. 22:1858–1867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kasai K, Ohara-Imaizumi M, Takahashi N,
Mizutani S, Zhao S, Kikuta T, Kasai H, Nagamatsu S, Gomi H and
Izumi T: Rab27a mediates the tight docking of insulin granules onto
the plasma membrane during glucose stimulation. J Clin Invest.
115:388–396. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang M, Bracaglia C, Prencipe G,
Bemrich-Stolz CJ, Beukelman T, Dimmitt RA, Chatham WW, Zhang K, Li
H, Walter MR, et al: A heterozygous RAB27A mutation associated with
delayed cytolytic granule polarization and hemophagocytic
lymphohistiocytosis. J Immunol. 196:2492–2503. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jiang S, Shen D, Jia WJ, Han X, Shen N,
Tao W, Gao X, Xue B and Li CJ: GGPPS-mediated Rab27A
geranylgeranylation regulates β cell dysfunction during type 2
diabetes development by affecting insulin granule docked pool
formation. J Pathol. 238:109–119. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kowluru A: A lack of ‘glue’ misplaces
Rab27A to cause islet dysfunction in diabetes. J Pathol.
238:375–377. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tolmachova T, Anders R, Stinchcombe J,
Bossi G, Griffiths GM, Huxley C and Seabra MC: A general role for
Rab27a in secretory cells. Mol Biol Cell. 15:332–344. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang JS, Wang FB, Zhang QG, Shen ZZ and
Shao ZM: Enhanced expression of Rab27A gene by breast cancer cells
promoting invasiveness and the metastasis potential by secretion of
insulin-like growth factor-II. Mol Cancer Res. 6:372–382. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dong WW, Mou Q, Chen J, Cui JT, Li WM and
Xiao WH: Differential expression of Rab27A/B correlates with
clinical outcome in hepatocellular carcinoma. World J
Gastroenterol. 18:1806–1813. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shi C, Yang X, Ni Y, Hou N, Xu L, Zhan F,
Zhu H, Xiong L and Chen P: High Rab27A expression indicates
favorable prognosis in CRC. Diagn Pathol. 10:682015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dong W, Cui J, Yang J, Li W, Wang S, Wang
X, Li X, Lu Y and Xiao W: Decreased expression of Rab27A and Rab27B
correlates with metastasis and poor prognosis in colorectal cancer.
Discov Med. 20:357–367. 2015.PubMed/NCBI
|
|
27
|
Wang Q, Ni Q, Wang X, Zhu H, Wang Z and
Huang J: High expression of RAB27A and TP53 in pancreatic cancer
predicts poor survival. Med Oncol. 32:3722015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hannafon BN, Carpenter KJ, Berry WL,
Janknecht R, Dooley WC and Ding WQ: Exosome-mediated microRNA
signaling from breast cancer cells is altered by the
anti-angiogenesis agent docosahexaenoic acid (DHA). Mol Cancer.
14:1332015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bobrie A, Krumeich S, Reyal F, Recchi C,
Moita LF, Seabra MC, Ostrowski M and Théry C: Rab27a supports
exosome-dependent and -independent mechanisms that modify the tumor
microenvironment and can promote tumor progression. Cancer Res.
72:4920–4930. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pierotti MA, Berrino F, Gariboldi M,
Melani C, Mogavero A, Negri T, Pasanisi P and Pilotti S: Targeting
metabolism for cancer treatment and prevention: Metformin, an old
drug with multi-faceted effects. Oncogene. 32:1475–1487. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Evans JM, Donnelly LA, Emslie-Smith AM,
Alessi DR and Morris AD: Metformin and reduced risk of cancer in
diabetic patients. BMJ. 330:1304–1305. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jiralerspong S, Palla SL, Giordano SH,
Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi
GN and Gonzalez-Angulo AM: Metformin and pathologic complete
responses to neoadjuvant chemotherapy in diabetic patients with
breast cancer. J Clin Oncol. 27:3297–3302. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu B, Fan Z, Edgerton SM, Deng XS,
Alimova IN, Lind SE and Thor AD: Metformin induces unique
biological and molecular responses in triple negative breast cancer
cells. Cell Cycle. 8:2031–2040. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Alimova IN, Liu B, Fan Z, Edgerton SM,
Dillon T, Lind SE and Thor AD: Metformin inhibits breast cancer
cell growth, colony formation and induces cell cycle arrest in
vitro. Cell Cycle. 8:909–915. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zakikhani M, Dowling R, Fantus IG,
Sonenberg N and Pollak M: Metformin is an AMP kinase-dependent
growth inhibitor for breast cancer cells. Cancer Res.
66:10269–10273. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen X, Li C, He T, Mao J, Li C, Lyu J and
Meng QH: Metformin inhibits prostate cancer cell proliferation,
migration, and tumor growth through upregulation of PEDF
expression. Cancer Biol Ther. 17:507–514. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Heckman-Stoddard BM, Gandini S, Puntoni M,
Dunn BK, DeCensi A and Szabo E: Repurposing old drugs to
chemoprevention: The case of metformin. Semin Oncol. 43:123–133.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cazzaniga M and Bonanni B: Relationship
between metabolic reprogramming and mitochondrial activity in
cancer cells. Understanding the anticancer effect of metformin and
its clinical implications. Anticancer Res. 35:5789–5796.
2015.PubMed/NCBI
|
|
39
|
Hirsch HA, Iliopoulos D, Tsichlis PN and
Struhl K: Metformin selectively targets cancer stem cells, and acts
together with chemotherapy to block tumor growth and prolong
remission. Cancer Res. 69:7507–7511. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Vazquez-Martin A, Oliveras-Ferraros C,
Cufí S, Del Barco S, Martin-Castillo B and Menendez JA: Metformin
regulates breast cancer stem cell ontogeny by transcriptional
regulation of the epithelial-mesenchymal transition (EMT) status.
Cell Cycle. 9:3807–3814. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Deng XS, Wang S, Deng A, Liu B, Edgerton
SM, Lind SE, Wahdan-Alaswad R and Thor AD: Metformin targets Stat3
to inhibit cell growth and induce apoptosis in triple-negative
breast cancers. Cell Cycle. 11:367–376. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Cazzaniga M and Bonanni B: Breast cancer
metabolism and mitochondrial activity: The possibility of
chemoprevention with metformin. Biomed Res Int. 2015:9721932015.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Iliopoulos D, Hirsch HA and Struhl K:
Metformin decreases the dose of chemotherapy for prolonging tumor
remission in mouse xenografts involving multiple cancer cell types.
Cancer Res. 71:3196–3201. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Cufi S, Corominas-Faja B, Vazquez-Martin
A, Oliveras-Ferraros C, Dorca J, Bosch-Barrera J, Martin-Castillo B
and Menendez JA: Metformin-induced preferential killing of breast
cancer initiating CD44+CD24−/low cells is
sufficient to overcome primary resistance to trastuzumab in
HER2+ human breast cancer xenografts. Oncotarget.
3:395–398. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Liu B, Fan Z, Edgerton SM, Yang X, Lind SE
and Thor AD: Potent anti-proliferative effects of metformin on
trastuzumab-resistant breast cancer cells via inhibition of
erbB2/IGF-1 receptor interactions. Cell Cycle. 10:2959–2966. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Guha P, Bandyopadhyaya G, Polumuri SK,
Chumsri S, Gade P, Kalvakolanu DV and Ahmed H: Nicotine promotes
apoptosis resistance of breast cancer cells and enrichment of side
population cells with cancer stem cell-like properties via a
signaling cascade involving galectin-3, α9 nicotinic acetylcholine
receptor and STAT3. Breast Cancer Res Treat. 145:5–22. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Saadin K and White IM: Breast cancer stem
cell enrichment and isolation by mammosphere culture and its
potential diagnostic applications. Expert Rev Mol Diagn. 13:49–60.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Tomizawa M, Shinozaki F, Motoyoshi Y,
Sugiyama T, Yamamoto S and Ishige N: Proliferation of
sphere-forming hepatocellular carcinoma cells is suppressed in a
medium without glucose and arginine, but with galactose and
ornithine. Oncol Lett. 13:1264–1268. 2017.PubMed/NCBI
|
|
50
|
Manuel Iglesias J, Beloqui I,
Garcia-Garcia F, Leis O, Vazquez-Martin A, Eguiara A, Cufi S, Pavon
A, Menendez JA, Dopazo J and Martin AG: Mammosphere formation in
breast carcinoma cell lines depends upon expression of E-cadherin.
PLoS One. 8:e772812013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Andriani F, Bertolini G, Facchinetti F,
Baldoli E, Moro M, Casalini P, Caserini R, Milione M, Leone G,
Pelosi G, et al: Conversion to stem-cell state in response to
microenvironmental cues is regulated by balance between epithelial
and mesenchymal features in lung cancer cells. Mol Oncol.
10:253–271. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Lacina L, Plzak J, Kodet O, Szabo P,
Chovanec M, Dvorankova B and Smetana K Jr: Cancer microenvironment:
What can we learn from the stem cell niche. Int J Mol Sci.
16:24094–24110. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Al Hilli MM, Bakkum-Gamez JN, Mariani A,
Cliby WA, McGree ME, Weaver AL, Dowdy SC and Podratz KC: The effect
of diabetes and metformin on clinical outcomes is negligible in
risk-adjusted endometrial cancer cohorts. Gynecol Oncol.
140:270–276. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Camacho L, Dasgupta A and Jiralerspong S:
Metformin in breast cancer-an evolving mystery. Breast Cancer Res.
17:882015. View Article : Google Scholar : PubMed/NCBI
|
